Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Ahmet Aydin

Concepts (132)

Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Urinary Bladder Neoplasms
7
2022
158
3.030
Why?
Penile Neoplasms
6
2021
44
2.960
Why?
Carcinoma, Squamous Cell
5
2021
326
1.910
Why?
Carcinoma, Transitional Cell
3
2022
51
1.520
Why?
Kidney Neoplasms
5
2021
174
1.490
Why?
Prostatic Neoplasms
3
2020
386
1.490
Why?
Lymphocytes, Tumor-Infiltrating
3
2021
77
1.410
Why?
Carcinoma, Renal Cell
4
2021
101
0.990
Why?
Immunotherapy
6
2021
234
0.860
Why?
Pheochromocytoma
1
2023
36
0.850
Why?
Adrenal Gland Neoplasms
1
2023
51
0.840
Why?
Urothelium
1
2021
17
0.720
Why?
BCG Vaccine
2
2020
16
0.700
Why?
Neoadjuvant Therapy
5
2022
119
0.690
Why?
Indocyanine Green
1
2020
34
0.690
Why?
Cancer Vaccines
1
2021
80
0.680
Why?
Ubiquitin Thiolesterase
2
2021
17
0.670
Why?
CD8-Positive T-Lymphocytes
1
2021
127
0.670
Why?
Adjuvants, Immunologic
1
2020
52
0.650
Why?
Patient Readmission
1
2021
229
0.640
Why?
Anesthesia, Local
1
2019
16
0.640
Why?
Immunotherapy, Adoptive
1
2021
161
0.630
Why?
Tumor Suppressor Proteins
2
2021
127
0.630
Why?
Edetic Acid
1
2019
14
0.630
Why?
Testicular Neoplasms
4
2021
45
0.620
Why?
Ureteral Neoplasms
1
2019
11
0.620
Why?
Prostate-Specific Antigen
1
2019
44
0.620
Why?
Papillomavirus Infections
1
2021
165
0.610
Why?
Oligopeptides
1
2019
94
0.590
Why?
Male
23
2021
25866
0.580
Why?
Neoplasm Recurrence, Local
4
2021
622
0.560
Why?
Cystectomy
3
2022
49
0.540
Why?
Humans
29
2023
50419
0.510
Why?
Arteriovenous Fistula
1
2016
30
0.510
Why?
Neoplasms, Germ Cell and Embryonal
3
2021
22
0.470
Why?
Antineoplastic Combined Chemotherapy Protocols
4
2022
997
0.450
Why?
Retrospective Studies
9
2022
6274
0.430
Why?
Middle Aged
11
2021
12579
0.420
Why?
Lymphatic Metastasis
4
2021
221
0.410
Why?
Aged
10
2021
9738
0.400
Why?
Neoplasm Grading
4
2020
122
0.390
Why?
Neoplasm Invasiveness
3
2022
269
0.370
Why?
Tumor Microenvironment
3
2021
221
0.350
Why?
Female
13
2023
27053
0.320
Why?
Lymph Nodes
2
2021
256
0.300
Why?
Treatment Outcome
7
2022
5265
0.280
Why?
Prognosis
3
2020
1974
0.250
Why?
Neoplasm Metastasis
3
2021
230
0.230
Why?
Postoperative Complications
3
2021
1030
0.230
Why?
Quality of Life
2
2020
850
0.220
Why?
Adrenalectomy
1
2023
34
0.220
Why?
Adrenal Glands
1
2023
39
0.220
Why?
Adult
8
2023
13561
0.210
Why?
Neoplasm Staging
3
2021
738
0.200
Why?
Aged, 80 and over
2
2021
3233
0.200
Why?
Deoxycytidine
1
2022
28
0.200
Why?
Retroperitoneal Space
2
2021
27
0.190
Why?
Cohort Studies
3
2021
1451
0.190
Why?
Muscles
1
2022
104
0.190
Why?
Mycobacterium bovis
1
2021
11
0.180
Why?
Antigens, Differentiation, Myelomonocytic
1
2021
39
0.180
Why?
Lymph Node Excision
2
2021
131
0.180
Why?
T-Lymphocytes
2
2020
325
0.180
Why?
Aftercare
1
2021
72
0.180
Why?
Teratoma
1
2021
22
0.180
Why?
Interleukin-2
1
2021
70
0.180
Why?
Reference Standards
1
2020
52
0.170
Why?
Tomography, Emission-Computed
1
2020
53
0.170
Why?
Fluorouracil
1
2020
59
0.170
Why?
Lymphocyte Activation
1
2021
169
0.170
Why?
Cisplatin
1
2022
283
0.170
Why?
Recurrence
2
2019
657
0.170
Why?
Carcinoma in Situ
1
2020
73
0.170
Why?
Antigens, CD
1
2021
221
0.170
Why?
Sentinel Lymph Node Biopsy
1
2020
118
0.160
Why?
Survival Rate
2
2019
906
0.160
Why?
Gallium Isotopes
1
2019
2
0.160
Why?
Gallium Radioisotopes
1
2019
10
0.160
Why?
Kidney Pelvis
1
2019
16
0.160
Why?
Patient Discharge
1
2021
318
0.160
Why?
Disease-Free Survival
1
2020
439
0.150
Why?
Genomics
1
2020
238
0.150
Why?
Feasibility Studies
1
2020
389
0.150
Why?
Papillomavirus Vaccines
1
2019
66
0.150
Why?
Ureteral Obstruction
1
2019
57
0.150
Why?
Urologic Neoplasms
1
2018
12
0.150
Why?
Carcinoma, Papillary
1
2018
47
0.140
Why?
Antineoplastic Agents
3
2020
1165
0.140
Why?
Genetic Predisposition to Disease
1
2020
507
0.140
Why?
Cells, Cultured
1
2021
1563
0.140
Why?
Biopsy
1
2019
588
0.140
Why?
Cell Proliferation
1
2021
980
0.130
Why?
Renal Artery
1
2016
32
0.130
Why?
Gene Expression Regulation, Neoplastic
1
2020
831
0.130
Why?
Nephrectomy
1
2016
78
0.130
Why?
Time Factors
2
2020
2933
0.120
Why?
Urinary Tract Infections
1
2015
51
0.120
Why?
Laparoscopy
1
2016
172
0.110
Why?
Prospective Studies
1
2020
2378
0.110
Why?
Kidney Failure, Chronic
1
2015
202
0.100
Why?
Kidney Transplantation
1
2015
189
0.100
Why?
Risk Factors
1
2019
3712
0.090
Why?
Chemotherapy, Adjuvant
2
2020
119
0.080
Why?
Kaplan-Meier Estimate
2
2021
462
0.080
Why?
Follow-Up Studies
3
2020
2231
0.070
Why?
Survival Analysis
2
2021
658
0.070
Why?
T-Lymphocyte Subsets
1
2021
38
0.040
Why?
Immune System
1
2021
43
0.040
Why?
Administration, Topical
1
2020
67
0.040
Why?
Forkhead Transcription Factors
1
2021
110
0.040
Why?
Urinary Bladder
1
2020
93
0.040
Why?
Patient Selection
1
2020
257
0.040
Why?
Treatment Failure
1
2019
120
0.040
Why?
Macrophages
1
2021
365
0.040
Why?
Socioeconomic Factors
1
2020
591
0.040
Why?
Oncolytic Virotherapy
1
2017
15
0.040
Why?
Health Facilities
1
2017
39
0.040
Why?
Combined Modality Therapy
1
2018
640
0.030
Why?
Adolescent
2
2019
6453
0.030
Why?
Turkey
1
2015
16
0.030
Why?
Mutation
1
2021
1275
0.030
Why?
Clinical Trials as Topic
1
2017
488
0.030
Why?
Child
2
2019
6931
0.030
Why?
Registries
1
2017
565
0.030
Why?
Graft Survival
1
2015
160
0.030
Why?
Cytokines
1
2017
602
0.030
Why?
Antibodies, Monoclonal
1
2017
460
0.030
Why?
Mice
1
2020
5659
0.020
Why?
Child, Preschool
1
2019
3953
0.020
Why?
Young Adult
1
2018
4075
0.020
Why?
United States
1
2017
5005
0.020
Why?
Animals
1
2020
13063
0.020
Why?
Aydin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description